EirGenix, Merck Sign Biologics Support Memorandum

The non-legally binding agreement supports EirGenix's IND- and BLA-enabling biologics pipeline development.

Updated on Nov. 12, 2026 in Biotech

Bold flat-color editorial illustration of two stainless steel bioreactor vessels joined by clear tubing in a clean room, evoking biologics manufacturing collaboration.
Merck will supply BioReliance cell line characterization, viral clearance, and lot release testing to EirGenix under a non-binding memorandum of understanding signed this week. AI Illustration. Upload story photo >

EirGenix and Merck signed a non-legally binding memorandum of understanding for biologics development support. Merck is also one of EirGenix's preferred contract testing services vendors for BioReliance services.

Why it matters

The collaboration combines EirGenix's biologics development and smart manufacturing capabilities with Merck's regulatory consultancy and GMP testing capabilities. It is intended to accelerate technical decision-making and support EirGenix's ability to meet international quality and regulatory expectations.

The BioReliance expansion in Singapore adds the Blazar tNGS Rodent Virus Panel, GMP NGS-based Adventitious-Agent Testing, and the Aptegra CHO genetic stability assay for cell line characterization. A new Darmstadt site handles drug substance and drug product release testing, though the announcement did not specify testing volumes or turnaround times.

The players

EirGenix Inc.

A New Taipei City, Taiwan-headquartered biologics developer listed on the Taiwan Stock Exchange under ticker 6589, focused on biologics development and smart manufacturing.

Merck

A global science and technology company with roughly 62,000 employees, whose BioReliance unit provides testing and regulatory consultancy services for biologics developers.

The details

Under the memorandum, Merck will provide BioReliance services for cell line characterization, viral clearance, genetic characterization and lot release testing. Singapore's BioReliance capabilities were expanded for cell line characterization, and a site was opened in Darmstadt for drug substance and drug product release testing.

Timeline

  1. November 12, 2026: EirGenix and Merck partnership announcement published.

The Tech Race

The partnership follows the broader biologics industry pattern of developers outsourcing GMP testing and regulatory consultancy to specialized vendors such as Merck's BioReliance. It positions EirGenix to compete in IND- and BLA-enabling development by relying on established contract testing infrastructure rather than building it in-house.

For patients, the partnership may eventually shorten the path to market for new biologic therapies by speeding up testing and regulatory decisions. Users should not expect any immediate change in drug availability or pricing from a non-binding memorandum.

The takeaway

Partnerships like this one show how biologics developers increasingly rely on specialized testing vendors to meet international regulatory standards. Watch for whether the collaboration produces binding agreements or additional site expansions in the coming months.

Further reading

For more on how drug developers are expanding testing and manufacturing partnerships, explore our Biotech coverage.

Source note: This article includes information reported by Pharmafocusasia.